IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA...